Protagonist Therapeutics, Inc
Close on Oct 19, 2026
- Market cap
- $9.55B
- P/E (TTM)
- 130.5
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $213.50M | $2.29 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $56.40M | $0.05 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | After market close | $7.40M | $-0.69 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $4.70M | $-0.62 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $5.55M | $-0.55 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $28.30M | $-0.19 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 21, 2025 | Before market open | $170.64M | $1.98 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $4.70M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | $4.20M | $-0.50 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | After market close | – | – | – |
Press releases
Announcements Protagonist Therapeutics filed with the SEC
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
COMPANY OVERVIEW Dinesh V. Patel, Ph.D. President & CEO August 5, 2026 1
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Protagonist Reports First Quarter 2026 Financial
Results of operations · EX-99.1 to Form 8-K
Protagonist Reports Fourth Quarter and Full
Results of operations · EX-99.1 to Form 8-K
COMPANY OVERVIEW Dinesh V. Patel, Ph.D. President & CEO January 12, 2026 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Icotrokinra Clinical Study Results Demonstrate
Other events · EX-99.1 to Form 8-K/A
Top Line Results from Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients with Ulcerative
Other events · EX-99.2 to Form 8-K/A
Icotrokinra Clinical Study Results Demonstrate
Other events · EX-99.1 to Form 8-K
Top Line Results from Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients with Ulcerative
Other events · EX-99.2 to Form 8-K
and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study
Other events · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113) in plaque psoriasis, a first-in-class
Material agreement · Other events · EX-99.1 to Form 8-K
Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Protagonist Reports First Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rusfertide Hepcidin Hormone Mimetic Addressing Unmet Needs in Polycythemia Vera
Other events · EX-99.1 to Form 8-K
COMPANY OVERVIEW Dinesh V. Patel, Ph.D. President & CEO January 08, 2024 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rusfertide (PTG - 300): Hepcidin Mimetic Addressing Unmet Needs in Polycythemia Vera
Other events · EX-99.1 to Form 8-K
Protagonist Reports First Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Protagonist Therapeutics Announces Topline Data
Regulation FD disclosure · EX-99.1 to Form 8-K
PN - 943 and IL - 23 Receptor Antagonists Oral Targeted Investigational Therapies for IBD and non - IBD indications 34
Other events · EX-99.1 to Form 8-K
Therapeutics Reports Fourth Quarter and Full Year 2021 Financial
Results of operations · EX-99.1 to Form 8-K
Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K